8.3 Hydrops Fetalis & Cardiovascular Failure

Hydrops Fetalis: Definition and Scope

Hydrops fetalis represents the end-stage manifestation of severe, decompensated fetal distress, characterized by abnormal fluid accumulation in multiple fetal compartments. It is not a disease in itself, but rather a clinical sign of underlying, severe pathology. Historically, Rh-alloimmunization was the predominant cause, leading to immune hydrops. However, with the widespread use of Rh(D) immune globulin (RhoGAM), non-immune hydrops fetalis (NIHF) now accounts for nearly 90% of all cases.

The sonographic diagnosis of hydrops fetalis requires the presence of abnormal fluid in at least two distinct fetal compartments. These compartments include:

1. Pericardial effusion: A rim of fluid >2 mm thick surrounding the heart. A small trace of fluid can be physiological, but >2 mm is abnormal.
2. Pleural effusion: Fluid surrounding the lungs, often causing pulmonary compression and secondary pulmonary hypoplasia.
3. Ascites: Fluid in the fetal peritoneal cavity, outlining the liver, bowel, and falciform ligament.
4. Skin edema (Anasarca): Generalized skin thickening measuring >5 mm, often most prominent over the fetal skull (scalp edema or halo sign) and body wall.
5. Placentomegaly: Often considered alongside fluid collections, an abnormally thickened, enlarged placenta is a common component. Polyhydramnios is also frequently associated due to decreased fetal swallowing or increased fetal urine output in high cardiac output states.

Cardiovascular causes are the single largest category of NIHF, responsible for approximately 25-40% of cases. When a fetus presents with hydrops, a detailed fetal echocardiogram is paramount to identifying or excluding a primary cardiac etiology.

Cardiovascular Causes of Hydrops Fetalis

Cardiac etiologies leading to hydrops can be broadly categorized into three pathophysiological mechanisms: structural defects causing severe heart failure, arrhythmias (tachycardias or bradycardias), and high-output cardiac failure.

1. Structural Heart Defects: Severe structural anomalies that lead to right-sided volume or pressure overload are most likely to cause hydrops, as elevated central venous pressure is the primary driver of fluid transudation.

• Ebstein Anomaly and Tricuspid Valve Dysplasia: Severe tricuspid regurgitation leads to massive right atrial dilation and directly elevates central venous pressure.
• Premature Closure of the Foramen Ovale or Ductus Arteriosus: Premature closure of the ductus arteriosus (often associated with maternal NSAID use, e.g., indomethacin) causes severe right ventricular pressure overload, leading to tricuspid regurgitation and right heart failure. Premature closure of the foramen ovale forces all right atrial return into the right ventricle, causing volume overload and potential failure.
• Left-sided Lesions: Severe left-sided lesions like Hypoplastic Left Heart Syndrome (HLHS) or critical aortic stenosis with endocardial fibroelastosis (EFE) can cause hydrops through left atrial hypertension, which backs up into the pulmonary bed and eventually causes secondary right heart failure, or through severe associated mitral regurgitation.

2. Fetal Arrhythmias: Both prolonged tachycardias and bradycardias severely compromise cardiac output, leading to heart failure and hydrops. The onset of hydrops in an arrhythmic fetus is a critical sign of decompensation and worsens the prognosis significantly.

• Tachyarrhythmias: Supraventricular Tachycardia (SVT) and atrial flutter (atrial rates 300-480 bpm) drastically shorten diastolic filling time. The reduced stroke volume causes elevated central venous pressure. Fetuses with sustained SVT >12 hours are at high risk for hydrops.
• Bradyarrhythmias: Complete Heart Block (ventricular rate often <55 bpm) forces the heart to rely entirely on increased stroke volume to maintain cardiac output. When compensatory mechanisms fail, cardiomegaly and eventual heart failure with hydrops ensue. The risk is significantly higher if structural anomalies are also present.

3. High-Output Cardiac Failure: This occurs when the heart must pump an excessively large volume of blood to meet metabolic demands or feed a vascular shunt. The high volume overload eventually leads to myocardial failure.

• Arteriovenous Malformations (AVMs): Large vascular shunts, such as a Vein of Galen aneurysmal malformation in the fetal brain, act as a massive low-resistance sink, requiring huge cardiac output.
• Vascular Tumors: Sacrococcygeal teratomas (SCT) can be highly vascular, acting similar to an AVM and precipitating high-output failure.
• Severe Fetal Anemia: Anemia (due to parvovirus B19 infection, fetomaternal hemorrhage, or alloimmunization) reduces oxygen-carrying capacity. The fetus compensates by increasing cardiac output. Over time, the volume overload and hypoxic stress on the myocardium lead to dilation, failure, and hydrops.
• Placental Abnormalities: A large placental chorioangioma acts as a vascular shunt.

Hemodynamic Staging: The Cardiovascular Profile Score (CVPS)

The Cardiovascular Profile Score (CVPS) is a widely utilized 10-point scoring system designed to systematically evaluate and stage the severity of fetal heart failure. It helps standardizing the assessment, guiding management, and predicting perinatal mortality. A normal score is 10. The score deduces points (up to 2 points per category) across five distinct variables:

1. Hydrops:
   • Normal: 2 points.
   • Ascites OR pleural/pericardial effusion: 1 point.
   • Skin edema (>5mm) AND other cavity fluid: 0 points.
2. Venous Doppler (Ductus Venosus/Umbilical Vein): Assesses right-sided filling pressures.
   • Normal flow: 2 points.
   • Absent or reversed a-wave in ductus venosus: 1 point.
   • Pulsatile flow in the umbilical vein (abnormal in 2nd/3rd trimester): 0 points.
3. Heart Size (Cardiothoracic Ratio):
   • Normal (area < 1/3 of chest): 2 points.
   • Enlarged (area 1/3 to 1/2 of chest): 1 point.
   • Severely enlarged (area > 1/2 of chest): 0 points.
4. Cardiac Function (AV Valve Regurgitation/Shortening Fraction):
   • Normal: 2 points.
   • Holosystolic tricuspid/mitral regurgitation OR abnormal ventricular function: 1 point.
   • Severe dP/dt abnormality or biphasic inflow: 0 points.
5. Arterial Doppler (Umbilical Artery): Assesses placental resistance.
   • Normal forward diastolic flow: 2 points.
   • Absent end-diastolic flow (AEDF): 1 point.
   • Reversed end-diastolic flow (REDF): 0 points.

A score of 10 indicates no signs of failure. Scores of 8-9 indicate mild dysfunction, 6-7 moderate distress, and scores ≤5 reflect severe, life-threatening heart failure with a high risk of imminent fetal demise.

Additional functional assessments include the Tei Index (Myocardial Performance Index - MPI), which evaluates both systolic and diastolic function by incorporating isovolumetric contraction and relaxation times alongside ejection time. An elevated Tei index indicates global myocardial dysfunction.

In Utero Management and Therapeutics

The management of hydrops depends entirely on the underlying etiology. When a cardiac cause is identified, specific interventions may be possible.

Anti-arrhythmic Therapy: For hydrops driven by SVT or atrial flutter, transplacental anti-arrhythmic therapy is the standard of care. Because a hydropic placenta transfers medication poorly, achieving therapeutic fetal drug levels is challenging. Digoxin is often the first line, but in the presence of hydrops, its efficacy is reduced. Sotalol or Flecainide are frequently utilized as second-line or even first-line agents in severe hydropic cases due to better placental transfer and efficacy. Amiodarone is reserved for refractory cases due to the risk of severe fetal hypothyroidism. Close maternal monitoring for pro-arrhythmic effects (e.g., QT prolongation with sotalol) is mandatory.

Intra-uterine Transfusion (IUT): If hydrops is due to severe fetal anemia (e.g., parvovirus B19 or alloimmunization), identified by elevated peak systolic velocity (PSV) in the middle cerebral artery (MCA), an intra-uterine intravascular blood transfusion via the umbilical vein can be lifesaving. Correcting the anemia resolves the high-output failure, and hydrops often reverses over several weeks.

Maternal Corticosteroids/Beta-agonists: For complete heart block with impending failure, maternal administration of sympathomimetics (terbutaline) may be attempted to increase the ventricular escape rate. Corticosteroids (dexamethasone) are used to reduce inflammation in immune-mediated block, though their efficacy in reversing established block is limited.

Fetoscopic Surgery/Interventions: For high-output states due to vascular tumors like sacrococcygeal teratoma, fetoscopic interventions (e.g., laser ablation of feeding vessels) or open fetal surgery might be considered in specialized centers if heart failure is progressive. For structural defects like critical aortic stenosis causing evolving HLHS, fetal aortic valvuloplasty may be performed to alter the natural history and potentially rescue the left ventricle, preventing severe heart failure.